All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
Astellas, Sangamo sign licensing agreement for genomic medicines
Sangamo will receive a $20m upfront license fee and is eligible to earn up to $1.3bn in additional licensed target fees and milestone payments across all five potential disease targets, along with tiered royalties
Ionis receives FDA approval for Tryngolza to treat rare disease FCS
Tryngolza is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic disease characterised by extremely elevated triglyceride levels
Novo Holdings completes $16.5bn acquisition of Catalent
Novo Holdings signed an agreement to acquire Catalent in February this year, which also includes Novo Nordisk acquiring Novo Holdings’ three fill-finish sites located in Anagni, Italy; Bloomington, US; and Brussels, Belgium
Merck gets rights to Hansoh Pharma’s investigational diabetes drug
Merck gets an exclusive global license to develop, manufacture and commercialise HS-10535, in exchange for an upfront payment of $112m and up to $1.9bn in milestone payments, along with royalties
Lilly, EVA Pharma secure regulatory approval for insulin in Egypt
EVA Pharma and Lilly partnered in 2022, to manufacture and supply high-quality human and analogue insulin to at least one million people living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs)
Merck to acquire organoid technology company HUB Organoids
The acquisition of HUB, which has the foundational patent portfolio on organoids, would enhance Merck’s portfolio of cell culture reagents, tools and benchtop instruments for academia, biotech, and pharma customers
Health Canada Approves XEOMINfor Post-stroke Lower Limb Spasticity in the Ankle and Foot
Canada is the third country to authorize XEOMIN for lower limb treatment based on data from a Japanese study (J-PLUS), which investigated the effects of XEOMIN on spasticity in Japanese stroke survivors
GSK secures EMA PRIME designation for investigational ADC
GSK’227 is an investigational B7-H3-targeted antibody-drug conjugate (ADC) and its PRIME Designation is based on preliminary clinical data from an ongoing open-label, multi-centre Phase 1 study, dubbed ARTEMIS-001
Novo Nordisk to build $ 1.2bn new facility in Odense, Denmark
Novo Nordisk will build an advanced finished production facility and warehouse covering more than 40,000m2 of area, to accommodate multiple product types within rare diseases, such as haemophilia
Emergent BioSolutions Receives $50m Contract Option from BARDA to Procure Doses of CYFENDUS
CYFENDUS® vaccine was approved by the U.S. Food & Drug Administration (FDA) in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals 18 through 65 years of age